Genor Biopharma Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2007-12-04
- Employees
- 101
- Market Cap
- -
- Website
- http://www.genorbio.com
Clinical Trials
24
Active:0
Completed:4
Trial Phases
3 Phases
Phase 1:16
Phase 2:4
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
Phase 1
16 (66.7%)Phase 2
4 (16.7%)Phase 3
4 (16.7%)A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT06934616
A Study of [14C]GB491 in Male Healthy Subjects
Phase 1
Completed
- Conditions
- Nonsmall Cell Lung CancerBreast Cancer
- Interventions
- Drug: [14C]GB491
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05860582
- Locations
- 🇨🇳
Beijing GoBroad Boren Hospital, Beijing, Beijing, China
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Phase 3
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT05851014
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The First Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Anhui Cancer Hospital, Hefei, Anhui, China
A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer
Phase 1
- Conditions
- Advanced Breast Cancer
- Interventions
- Drug: GB491+Letrozole
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT05337657
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor
Phase 1
Recruiting
- Conditions
- NSCLCOther Solid Tumors
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05332574
- Locations
- 🇦🇺
Genesis Care, Saint Leonards, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺Cabrini Hospital Malvern, Malvern, Victoria, Australia
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found